This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The Cooper Companies Announces First Quarter 2013 Results

PLEASANTON, Calif., March 7, 2013 (GLOBE NEWSWIRE) -- The Cooper Companies, Inc. (NYSE:COO) today announced financial results for the fiscal first quarter ended January 31, 2013.

  • Revenue increased 16% year-over-year to $379.8 million. CooperVision (CVI) revenue up 12% to $301.4 million, and CooperSurgical (CSI) revenue up 37% to $78.4 million.
  • GAAP earnings per share (EPS) $1.50, up 38 cents or 34% from last year's first quarter. Includes final business interruption insurance proceeds of $14.1 million related to damage in one of our UK manufacturing facilities from October 2011.
  • Non-GAAP EPS $1.23, up 11 cents from last year's first quarter. See "Reconciliation of Non-GAAP EPS to GAAP EPS" below.

Commenting on the results, Robert S. Weiss, Cooper's president and chief executive officer said, "We began fiscal 2013 with a very solid first quarter. Revenues grew nicely with CVI continuing to show strong Biofinity ® growth and CSI posting strong growth in the fertility category. Our investment strategies are continuing to prove positive as indicated by our market share gains, and we remain optimistic about the future."

First Quarter GAAP Operating Highlights

  • Revenue $379.8 million, up 16% from last year's first quarter, 11% excluding currency and acquisitions.  
  • Gross margin 63% compared with 65% in last year's first quarter. The decrease was primarily the result of lower revenue due to currency, primarily the yen, and higher cost inventory associated with the relaunch of Avaira ®.  
  • Operating margin 18% compared with 19% in last year's first quarter. The decrease was the result of lower gross margin offset by positive SG&A leverage.  
  • Depreciation $24.1 million, up 19% from last year's first quarter. Amortization $7.4 million, up 33% from last year's first quarter, primarily related to intangible assets from the acquisition of Origio.  
  • Total debt increased $34.3 million in the quarter to $408.0 million, due to $44.4 million of share repurchases (460 thousand shares). Interest expense $2.6 million compared with $3.7 million in last year's first quarter.  
  • Cash provided by operations $47.6 million, capital expenditures $29.3 million, insurance recovery $0.6 million, and excluding acquisition costs of $0.3 million resulted in free cash flow $19.2 million. 

First Quarter CooperVision GAAP Operating Highlights

  • Revenue $301.4 million, up 12% from last year's first quarter, 14% in constant currency.  
  • Revenue by category:  
        Constant Currency
  (In millions) % of CVI Revenue %chg %chg
  1Q13 1Q13 y/y y/y
Toric  $ 91.6 30% 12% 13%
Multifocal  27.2 9% 31% 31%
Single-use sphere  65.5 22% 8% 13%
Non single-use sphere, other  117.1 39% 11% 12%
Total  $ 301.4 100% 12% 14%
  • Revenue by geography:
        Constant Currency
   (In millions)  % of CVI Revenue %chg %chg
   1Q13  1Q13 y/y y/y
Americas  $ 125.0 41% 18% 18%
EMEA  101.9 34% 7% 7%
Asia Pacific  74.5 25% 10% 17%
Total  $ 301.4 100% 12% 14%
         
  • Selected revenue by material:
        Constant Currency
   (In millions)  % of CVI Revenue %chg %chg
   1Q13  1Q13 y/y y/y
         
Silicone hydrogel  $ 119.6 40% 38% 38%
Proclear®  $ 75.5 25% 7% 8%
  • Gross margin 63% compared with 64% in last year's first quarter. The decrease was primarily the result of lower revenue due to currency, primarily the yen, and higher cost inventory associated with the relaunch of Avaira ®.

First Quarter CooperSurgical GAAP Operating Highlights

  • Revenue $78.4 million, up 37% from last year's first quarter, up 1% excluding acquisitions.   
  • Revenue by category:
  (In millions) % of CSI Revenue %chg
  1Q13 1Q13 y/y
Office, other  $ 29.5 38% -3%
Surgical procedures  24.9 32% 9%
Fertility  24.0 30% 535%
Total  $ 78.4 100% 37%
       
  • Gross margin 64% compared with 67% in last year's first quarter. The decrease was primarily the result of lower margins associated with our recently acquired Origio business.

2013 Guidance

The Company revises its full year fiscal 2013 guidance. Guidance is summarized as follows:

  FY13 Guidance FY13 Guidance
  Old New
Revenues (In millions)    
Total $1,565-$1,625 $1,575-$1,625
CVI $1,250-$1,290 $1,260-$1,290
CSI $315-$335 $315-$335
EPS    
GAAP $5.90-$6.10 $6.22-$6.37
Non-GAAP $5.90-$6.10 $5.95-$6.10
Free Cash Flow (In millions) $210-$230 $170-$200

Guidance assumes constant currency at the date of issuance.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,918.71 -41.86 -0.25%
S&P 500 1,971.01 -7.33 -0.37%
NASDAQ 4,423.6240 -25.94 -0.58%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs